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Experts Recommend Treating Cancer
Pain in the Context of Other Symptoms
by David Galloway

n

renal
cell carcinoma
metastasized
to his lungs and bones, the pain
was so severe that it clouded
every aspect of his life.
Mr.-wife,. felt helpless to
allay her husband's suffering. ''When a
person is in a lot of pain, it is like he
doesn't care anymore about anything.
He cannot eat; he cannot enjoy watching
TV; he cannot enjoy talking to his
family," said Mrs. - whose husband
died in August 2003. ''When he was
in pain, it was terrible, because pain
makes a person very weak. You don't have
anything at all left, no energy, nothing."
As thellll learned, however,
pain is no longer something that
patients with cancer must simply
learn to live with. Mr.-pain
and other symptoms were alleviated
through a combination of supportive
care, medications, and spinal nerve
blockade.
Researchers now consider pain to
be just one part of a matrix of symptoms
to be assessed and treated as a whole.
Pain is interwoven with fatigue, nausea,
depression, anxiety, drowsiness, short
ness of breath, loss of appetite, insom-

... holds a photograph of her husband,
, who was treated
at M. D. Anderson Cancer Center for renal cell carcinoma. New research into treating
cancer pain in the context of other symptoms has eased the burden of pain for many
patients such as Mr.1111 who received supportive care, medications, and a spinal
nerve blockade for his pain and other symptoms before he died in August 2003.
nia, and a diminished sense of well
being. In essence, clinicians are begin
ning to learn and apply what, on some
level, patients have always known: the
(Continued on next page)
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showed that one in five outpatients
rated their pain as seven or higher.
Researchers are now studying how
various symptoms might be linked
together. “A lot of these symptoms that
occur together seem to be related to an
inflammatory response to the therapy
for cancer,” Dr. Cleeland said. The insult
of therapy generates cytokines, which
appear to cause not only pain but also
lethargy, loss of interest, diminished
learning capacity, and other problems in
animal models. If these results translate
to clinical studies, as expected, the
treatment of symptoms could be simplified. “Patients with seven or eight
symptoms may not need to take
seven or eight drugs,” Dr. Bruera said.
Some of the changes in pain
management are the result of changes
in physician attitudes toward cancer
treatment. “Before, we thought that
all the problems that our patients had
were brought on by the cancer,” Dr.
Bruera said. A person was considered
healthy until cancer struck, and all
subsequent problems were blamed on
the cancer. Now, oncologists are paying
more attention to premorbid conditions,
such as chronic depression, alcohol
abuse, personality disorders, fatigue,
and chronic infections. “And cancer
comes on top of that,” Dr. Bruera said.
“So all these symptoms and disease
problems are a consequence of both
the cancer and what was there before.”
For patients like
and
their families, advances in the understanding and treatment of pain can make
a real difference. Seeing her husband’s
pain under control made his illness more
bearable for her and for the couple’s
children, said
. “When there
was no pain, or less pain, he was able to
eat; he was able to have conversations; he
was able to watch the TV. It’s hard to see
somebody in pain, especially somebody
that you love,” she said. “It’s very hard.”
Lifting that burden from patients and
their families is the greatest benefit of
effective pain management. ●
FOR MORE INFORMATION, contact
Dr. Bruera at (713) 792-6084,
Dr. Cleeland at (713) 745-3470,
or Dr. Burton at (713) 745-7246.
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Participation of Elderly Patien
by Dawn Chalaire

C

ancer, it is often said, is a disease of the elderly.
The complex cellular processes that culminate in
malignancy usually take decades to become evident,
and a diagnosis of cancer often coincides with other
chronic diseases and advanced age. It is ironic, then, that those
who are most likely to have cancer are sometimes excluded from
studies of cancer treatments. The reasons behind these exclusions
are usually well intentioned, but that does not make them excusable, according to Leonard Zwelling, M.D., the vice president of
Research Administration, whose office oversees all research conducted at The University of Texas M. D. Anderson Cancer Center.
“People who are elderly, whatever
that means, can be put in a trial and
be successfully treated with chemotherapy and can benefit from it as much
as young people,” Dr. Zwelling said.
“Particularly when people get above
age 60 or 70, their physiologic age is
probably more important than their
chronologic age. Certain people are frail
enough that they shouldn’t go into trial
even if they’re 50. Other people have
a performance status that is fantastic
when they’re 80, and denying them
access to a clinical trial is a bad idea.”
Defining “elderly”
As Dr. Zwelling alluded to, “elderly”
is one of those words that everyone
seems to understand but no one can
really define. Even Merriam-Webster’s
Collegiate Dictionary has trouble nailing
it down and settles on the somewhat
circular definition of “rather old.”
Is someone elderly at 55, when they
receive their American Association of
Retired Persons (AARP) membership?
At 65, when they can begin collecting
Social Security retirement benefits?
Or at 70 or even 80?
“I’m sure I don’t know why it would
matter,” said Dr. Zwelling. “The point
of what people are talking about now
is that it doesn’t matter.”
Despite his AARP membership, it
is unlikely that anyone would use the
word “elderly” to describe Dr. Zwelling.
Slender and fit, even relaxing in his

high-backed office chair, he gives the
impression of barely contained energy.
His words come out in sharp bursts,
and his eyes are piercing.
“When you talk about giving people
access to health care or access to clinical
research, either way, I think it’s wrong
to discriminate on the basis of age,” he
said. “It’s the kind of logic that has been
used to be prejudicial and discriminatory for centuries, and it still stinks.
It’s still wrong.”
The current debate
According to the National Cancer
Institute (NCI), for all cancers combined, the incidence rate in people 65
and older is 10 times higher than the
rate for younger people, and the mortality rate is 16 times higher. The number
of people in the United States who are
65 and older is expected to double by
the year 2030.
A study published in 1999 in the
New England Journal of Medicine found
that while 63% of people in the general
population age 65 or older had cancer,
only 25% of patients in that age group
were represented in clinical trials.
At least two studies suggest that
physician bias may contribute to the
lack of participation among the elderly.
In a 1994 survey in the Journal of
Clinical Oncology, up to 50% of physicians said that they did not offer clinical
trials to patients solely on the basis of
age. In another study presented at the

nts in Clinical Trials: Looking Beyond Age
Ann Weiser, M.D., Ph.D.,
an associate professor
in the Department of
General Internal Medicine, Ambulatory Treatment, and Emergency
Care. “But again, it
doesn’t have to do with
age. If someone is 90, and
they don’t have any other
medical problems, and
they get a cancer, if they
want to be treated for it—
even though, maybe, the
treatment is not going to
cure them and it is going
to make them sick—if
they want to try it, I think
that they should be given
the option.”
A study published in
April 2003 in the Journal
of Clinical Oncology casts
doubt on the practice of
Dr. Luis Fayad, an assistant professor in the Department of Lymphoma, examines patient
the wholesale use of
. According to Dr. Fayad, many elderly patients have a very open mind about clinical trials
comorbid conditions as
and are willing to participate for the sake of advancing scientific knowledge.
exclusion criteria in
clinical trials. The study
2000 annual meeting of the American
“If you have a 50-year-old with
found that such protocol exclusions
Society of Clinical Oncology, physicoronary artery disease and renal failure, account for almost all of the undercians asked 51% of patients younger
he has a far greater risk of toxicities
representation of older people in cancer
than 65 to participate in clinical trials
from drugs than would an 80-year-old
clinical trials. Fewer older people were
but only 35% of patients over 65. In
who is physiologically fine, who has a
enrolled in trials that excluded patients
most cases, physician bias stems from
good performance status,” Dr. Zwelling
with high blood pressure; other heart,
the assumption that older people
said.
lung, or blood abnormalities; or limitacannot withstand cancer treatment or
It is true, however, that in general
tions on their ability to perform daily
that the risk and discomfort of certain
older people are more likely to have
living functions without help. The
treatments are not worth the benefits.
comorbid conditions and a poorer
researchers recommended that protocol
“But unless you ask the question, you performance status. The most common
exclusions be based solely on the
don’t really know that, do you?” said Dr. comorbid conditions that could make
specific toxicity of the regimen.
Zwelling. “The place where you want to patients ineligible for a clinical trial
“Hopefully, [a researcher’s] comorbid
include older people is in the trial so
are hypertension, diabetes, and vascular exclusions are chosen for a reason,” said
that you can begin to establish if there
disease. Reduced kidney, liver, or lung
Dr. Zwelling. “You’re not just sort of
are significant differences between the
function can also preclude certain
plucking them off a shelf. In a phase I
way they respond and the way younger
treatments. However, a history of
trial, it should be linked to what you see
patients respond.”
comorbid conditions alone should not
in animals. After that, you should have
prevent someone from entering a trial,
enough information from humans to
Better criteria
provided that the condition has been
know what the drug is likely to do and
Performance status—which
well controlled.
what its toxicity is likely to be.”
takes into account level of activity,
“Just because you have [a comorbid
ambulation, and ability to care for
condition] does not mean you won’t be
The effects of aging
oneself—and the presence of comorbid
able to get treatment. However, if it is
While age alone should never make
conditions that may be exacerbated by
poorly controlled and you have complia patient ineligible for a trial or other
the treatment are more reliable criteria
cations related to it, then it could affect treatment, the effects of aging on bodily
for clinical trial eligibility than age.
your ability to get treatment,” said Mary
(Continued on page 6)
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